日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Colorectal cancer statistics, 2026

2026年结直肠癌统计数据

Siegel, Rebecca L; Wagle, Nikita Sandeep; Star, Jessica; Kratzer, Tyler B; Smith, Robert A; Jemal, Ahmedin

Interventional oncology: A primer for clinicians on the role of ablation and embolization for solid tumors

介入肿瘤学:临床医生了解消融和栓塞在实体瘤治疗中的作用

Abdelsalam, Mohamed E; Ahrar, Kamran; Sheth, Rahul A; Shah, Ketan Y; Yevich, Steven; Gurusamy, Varshana; Odisio, Bruno C; Tam, Alda L; Mahvash, Armeen; Habibollahi, Peiman

Personalizing therapies over the course of hormone receptor-positive/HER2-negative metastatic breast cancer

在激素受体阳性/HER2阴性转移性乳腺癌的治疗过程中,制定个性化治疗方案

Singareeka Raghavendra, Akshara; Damodaran, Senthil; Barcenas, Carlos H; Fuqua, Suzanne A; Layman, Rachel M; Tripathy, Debu

Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers

2025年泌尿系统晚期肿瘤共识会议(AUC3):肾细胞癌和泌尿系统肿瘤治疗的专家共识

McKay, Rana R; Pal, Sumanta; Xie, Wanling; Aggen, David; Albiges, Laurence; Apolo, Andrea; Atkins, Michael B; Bangs, Rick; Beckermann, Kathryn E; Bellmunt, Joaquim; Berg, Stephanie A; Bilen, Mehmet A; Braun, David; Carlo, Maria I; Efstathiou, Jason; Galsky, Matthew; Grivas, Petros; Gupta, Shilpa; Haas, Naomi; Hakimi, A Ari; Hammers, Hans; Heng, Daniel Y C; Hirsch, Michelle; Iyer, Gopakumar; Jonasch, Eric; Koshkin, Vadim S; Kryvenko, Oleksandr; Lewis, Bryan; Li, Roger; Matin, Surena; Maughan, Benjamin; McDermott, David F; McGregor, Bradley; Meeks, Joshua; Milowsky, Matthew; Motzer, Robert; Necchi, Andrea; Petrylak, Dan; Porten, Sima; Powles, Thomas; Rini, Brian; Shuch, Brian; Siefker-Radtke, Arlene; Sonpavde, Guru; Sridhar, S Srikala; Suarez, Cristina; Tang, Chad; Tripathi, Abhishek; Van Der Heijden, Michiel S; Voss, Martin; Xu, Wenxin; Zhang, Tian; Rosenberg, Jonathan; Choueiri, Toni K

Biochemistry and regulation of histone lysine L-lactylation

组蛋白赖氨酸L-乳酰化的生物化学和调控

Sheng, Xinlei; Lin, Hening; Cole, Philip A; Zhao, Yingming

Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer

阿特珠单抗联合FOLFOX方案治疗III期错配修复缺陷型结肠癌

Sinicrope, Frank A; Ou, Fang-Shu; Arnold, Dirk; Peters, Walter R; Behrens, Robert J; Lieu, Christopher H; Matin, Khalid; Cohen, Deirdre J; Potter, Samara L; Nixon, Andrew B; Kottschade, Lisa A; Kathol, Emily; Frankel, Wendy L; Shergill, Ardaman; Hsu, Dennis; Reinacher-Schick, Anke; Mehan, Paul; Gold, Philip J; Khalil, Maged F; Zemla, Tyler; Gatten, Clare; O'Reilly, Eileen M; Meyerhardt, Jeffrey A

The evolving landscape of leptomeningeal metastases from NSCLC: an international, contemporary, multicenter cohort study

非小细胞肺癌软脑膜转移的演变格局:一项国际性、当代、多中心队列研究

Zheng, M M; Xia, Y; Pan, K; Sun, F; Tan, A C; Dong, X R; Tu, H Y; Tang, L B; Li, Y S; Yin, K; Borgeaud, M; Singhal, S; Zhu, E; Zhang, J; Nilsson, M; Wu, J; Gibbons, D L; Wakelee, H; Neal, J W; Lee, J; Vaporciyan, A A; Ringsurongkawong, W; Tran, H T; Zhang, R Z; Zhang, T; Zhou, Q; Zhong, W Z; Li, W; Zhang, Y C; Riess, J W; Addeo, A; Heymach, J V; Myall, N; Tan, D; Wu, Y L; Le, X

Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial

CheckMate 9ER 随机 III 期试验中,对纳武利尤单抗联合卡博替尼治疗晚期肾细胞癌的最终分析

Motzer, R J; Escudier, B; Burotto, M; Powles, T; Apolo, A B; Bourlon, M T; Shah, A Y; Porta, C; Suárez, C; Barrios, C H; Richardet, M; Gurney, H; Kessler, E R; Tomita, Y; Bedke, J; Scheffold, C; Askelson, M; Panzica, J; Zhang, J; van Kooten Losio, M; Choueiri, T K

A multicenter randomized phase II trial of lenvatinib plus everolimus versus cabozantinib in patients with metastatic clear-cell RCC that progressed on PD-1 immune checkpoint inhibition (LenCabo)

一项多中心随机 II 期试验,比较乐伐替尼联合依维莫司与卡博替尼治疗 PD-1 免疫检查点抑制剂治疗后进展的转移性透明细胞肾细胞癌患者的疗效(LenCabo)

Hahn, A W; Chahoud, J; Skelton, W P; Yuan, Y; Zurita-Saavedra, A J; Kovitz, C; Alhalabi, O; Campbell, M T; Jonasch, E; Lin, J K; Desai, M; Santos, M J M N; Hwang, H; Corn, P G; Msaouel, P; Tannir, N M

MTAP Loss Is Frequent in Oncogene-Driven NSCLC and May Confer Sensitivity to Combined PRMT5 Inhibitors and Targeted Therapies

MTAP缺失在癌基因驱动的非小细胞肺癌中很常见,并可能使肿瘤对PRMT5抑制剂和靶向治疗联合治疗敏感。

Aldea, M; Lenahan, S; Locquet, M-A; Liao, L; Gasparro, M; Gokhale, P C; Ghigna, M-R; Ionescu, D N; Odintsov, I; Ngo, K; Wang, X; Aziz, S; Pecci, F; Garbo, E; Ivanova, E; Nakazawa, S; Kulesza, J; Tsai, J A; Zullo, L; Lee, J; Zielinska, M; Simon, S; Han, D; Marinello, A; Li, G; Rossato de Almeida, G; Huang, J; Paoloni, F; Gariazzo, E; Santo, V; Remon, J; Marks, J A; LoPiccolo, J; Florez, N; Nishino, M; Ricciuti, B; Luo, J; Barbie, D A; Planchard, D; Rotow, J K; Barlesi, F; Graf, R P; Feng, W W; Besse, B; Paweletz, C; Sholl, L; Shaw, A T; Jänne, P A